Empagliflozin Treatment for Kidney Transplant Recipients
This study is looking at how safe and effective a drug called Empagliflozin is for people who have received a kidney transplant. Empagliflozin is an SGLT2 inhibitor, a type of medicine that has shown benefits for the kidneys and heart in other studies. This trial wants to see if it can help kidney transplant recipients, who often face long-term heart problems. You might be able to join if you are an adult (19 or older) who has had a kidney transplant at least 3 months ago. If you have type 2 diabetes or post-transplant diabetes, your kidney function (eGFR) must be at least 30mL/min. The main goal is to see how many people stop taking Empagliflozin over about two years. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 264 adult participants who have received a kidney transplant.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, discontinuation of Empagliflozin, will be measured at about two years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Empagliflozin Treatment in Kidney Transplant Recipients
At a glance
Conditions
Where it's being run
5 sites across 5 statesStudy leadership
- Roslyn B Mannon, MD · PRINCIPAL_INVESTIGATOR · Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Discontinuation of Empagliflozinabout 2 years
The incidence of therapeutic discontinuation of empagliflozin in the kidney transplant recipient from time of initiation.